Hepatic stellate cells, liver innate immunity, and hepatitis C virus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 112-115

  Wang, Yizhong ^a,b   Li, Jieliang ^b   Wang, Xu ^b   Sang, Min ^a   Ho, Wenzhe ^a,b  

^a WUHAN UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatic stellate cells; Hepatitis C virus; Innate immunity; Retinoic acid inducible gene I; Toll like receptor 3

Indexed keywords

GAMMA INTERFERON; INTERFERON; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3;

HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; LIVER CELL; LIVER FIBROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STELLATE CELL; VIRUS REPLICATION;

EID: 84880412360     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12023     Document Type: Review

References (44)

1. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953-960.
2. Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct. Funct. 2003; 28: 105-112.
3. Senoo H. Structure and function of hepatic stellate cells. Med. Electron Microsc. 2004; 37: 3-15.
4. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver Dis. 2001; 21: 311-335.
5. Glassner A, Eisenhardt M, Kramer B etal. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab. Invest. 2012; 92: 967-977.
6. Jeong WI, Park O, Suh YG etal. Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology 2011; 53: 1342-1351.
7. Kramer B, Korner C, Kebschull M etal. Natural killer p46(High) expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 2012; 56: 1201-1213.
8. Wang YZ, Ye L, Wang X etal. Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. Innate Immun. 2012 Oct 11 [Epub ahead of print]. DOI: 10.1177/1753425912460414.
9. Ichikawa S, Mucida D, Tyznik AJ etal. Hepatic stellate cells function as regulatory bystanders. J. Immunol. 2011; 186: 5549-5555.
10. Radaeva S, Wang L, Radaev S etal. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G809-816.
11. Radaeva S, Sun R, Jaruga B etal. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452.
12. Wang B, Trippler M, Pei R etal. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J. Hepatol. 2009; 51: 1037-1045.
13. Winau F, Hegasy G, Weiskirchen R etal. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007; 26: 117-129.
14. Park O, Jeong WI, Wang L etal. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009; 49: 1683-1694.
15. Wang YZ, Li JL, Wang X etal. Induction of interferon-λ contributes to Toll-like receptor-3 activated hepatic stellate cells-mediated hepatitis C virus inhibition in hepatocytes. J. Viral Hepat. 2012; DOI: 10.1111/jvh.12040.
16. Schuppan D, Krebs A, Bauer M etal. Hepatitis C and liver fibrosis. Cell Death Differ. 2003; 10 (Suppl. 1): S59-67.
17. Schulze-Krebs A, Preimel D, Popov Y etal. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005; 129: 246-258.
18. Deng L, Adachi T, Kitayama K etal. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J. Virol. 2008; 82: 10375-10385.
19. Aweya JJ, Tan YJ. Modulation of programmed cell death pathways by the hepatitis C virus. Front. Biosci. 2011; 16: 608-618.
20. Jiang JX, Mikami K, Shah VH etal. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology 2008; 48: 1497-1505.
21. Zhan SS, Jiang JX, Wu J etal. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-443.
22. Gieseler RK, Marquitan G, Schlattjan M etal. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J. Viral Hepat. 2011; 18: 760-767.
23. Mazzocca A, Carloni V, Sciammetta S etal. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J. Hepatol. 2002; 37: 322-330.
24. Cormier EG, Tsamis F, Kajumo F etal. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl Acad. Sci. U.S.A. 2004; 101: 7270-7274.
25. Mazzocca A, Sciammetta SC, Carloni V etal. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J. Biol. Chem. 2005; 280: 11329-11339.
26. Bataller R, Paik YH, Lindquist JN etal. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004; 126: 529-540.
27. Reynaert H, Thompson MG, Thomas T etal. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-581.
28. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
29. Coenen M, Nischalke HD, Kramer B etal. Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll-like receptor 2. Lab. Invest. 2011; 91: 1375-1382.
30. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007; 13: 1324-1332.
31. Watanabe A, Hashmi A, Gomes DA etal. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46: 1509-1518.
32. Kawai T, Akira S. Innate immune recognition of viral infection. Nat. Immunol. 2006; 7: 131-137.
33. Kumar A, Zhang J, Yu FS. Toll-like receptor 3 agonist poly(I : C)-induced antiviral response in human corneal epithelial cells. Immunology 2006; 117: 11-21.
34. Starace D, Galli R, Paone A etal. Toll-like receptor 3 activation induces antiviral immune responses in mouse sertoli cells. Biol. Reprod. 2008; 79: 766-775.
35. West J, Damania B. Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J. Virol. 2008; 82: 5440-5449.
36. Alexopoulou L, Holt AC, Medzhitov R etal. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
37. Wang N, Liang Y, Devaraj S etal. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 2009; 83: 9824-9834.
38. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002; 20: 197-216.
39. Li J, Ye L, Wang X etal. Induction of interferon-lambda contributes to toll-like receptor 3-mediated herpes simplex virus type 1 inhibition in astrocytes. J. Neurosci. Res. 2011; 90: 399-406.
40. Ank N, Iversen MB, Bartholdy C etal. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 2008; 180: 2474-2485.
41. Zhou L, Wang X, Wang YJ etal. Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience 2009; 159: 629-637.
42. Rehwinkel J, Tan CP, Goubau D etal. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010; 140: 397-408.
43. Fujita T, Onoguchi K, Onomoto K etal. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 2007; 89: 754-760.
44. Saito T, Owen DM, Jiang F etal. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527.